Are you Dr. Afif?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 6 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Waqqas Afif, MD is a gastroenterologist in Rochester, Minnesota. He is affiliated with Mayo Clinic Hospital - Rochester.
Clinical Trials
- TDM Guided Early Optimization of ADAL in Crohn's Disease Start of enrollment: 2017 Jan 17
Publications & Presentations
PubMed
- 1 citationsAdherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study.Panu Wetwittayakhlang, Petra A Golovics, Alex Al Khoury, Elie Ganni, Gustavo Drügg Hahn
Journal of Gastrointestinal and Liver Diseases. 2022-12-16 - 16 citationsEarly Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.Silvio Danese, Bruce E Sands, Maria T Abreu, Christopher D O'Brien, Ivana Bravatà
Clinical Gastroenterology and Hepatology. 2022-12-01 - 50 citationsEfficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.Maria T Abreu, David S Rowbotham, Silvio Danese, William J Sandborn, Ye Miao
Journal of Crohn's & Colitis. 2022-08-30
Press Mentions
New STELARA® (Ustekinumab) Long-Term Data Support Its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative ColitisMarch 4th, 2023- VIDEO: Stelara Safe, Effective for the Long-Term Treatment of Moderate to Severe UCOctober 21st, 2022
- Janssen Touts Positive Mid-Late Stage Data from Two Ulcerative Colitis TrialsOctober 10th, 2022
- Join now to see all
